Molecular Epidemiology of High-Risk Human Papilloma Virus Infection in Sexually Active Women at Bobo-Dioulasso University Teaching Hospital

Souleymane Ouattara¹, Der Adolphe Somé¹, Adama Dembélé¹, Salif Sanfo³, Théodorat Zohoncon², Abdoul-Karim Ouattara², Moussa Bambara², Blami Dao¹, Jacque Simporé²

¹Université Nazi Boni, Bobo-Dioulasso, Burkina Faso
²Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université de Ouagadougou, Université Ouaga I professeur Joseph Ki Zerbo, Ouagadougou, Burkina Faso
³CHU Souro Sanou, Bobo-Dioulasso, Burkina Faso
Email: ouaramels@yahoo.fr

Abstract
The objective of this study was to determine the prevalence of HPV-HR genotypes in the population of sexually active women in Bobo-Dioulasso, Burkina Faso. Methods: This study took place at Souro Sanou Teaching Hospital in Bobo-Dioulasso from September to June 2017. A total of 234 women in the gynecological period and also sexually active were enrolled after they gave an individual consent. Swabbing of the endocervical canal was done. From the sample stored at −20°C, the viral DNA was extracted using the “DNA-Sorb-A” kit from SACACE biotechnologies®. Amplification of the PCR of the extracted DNA was made, using the “HPV Genotypes 14 Real-TM Quant” V67-100 FRT kit. Data were analyzed with SPSS software version 17.0 and Epi Info 6. Chi-square and Fisher’s tests were used to compare proportions and averages; a link was significant when p < 0.05. Results: The mean age was 30.7 ± 7.3 years (median: 30 years); 84.5% of them were married, 43.5% had a socio-professional activity and 61% were schooled. A total of 20.6% of women were positive for at least one of the following HPV-HR genotypes: HPV 18, 31, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Genotypes the most frequently found were HPV 52 with 11 cases (17.2%) and 66 with 10 cases (15.6%). Conclusion: Our results show a predominance of HPV-HR genotypes not covered by available vaccines. Mapping genotypes are needed to fully understand viral ecology at the national level. But for instance, the nonavalent vaccine, which has a better coverage of the predominant genotypes, is to be promoted.
Keywords
HPV-HR, Epidemiology, Genotypes, Bobo-Dioulasso

1. Introduction

Human papillomavirus (HPV) genital infection is considered to be the most common sexually transmitted infection (STI) worldwide [1]. There are more than 100 genotypes, some of which are known as high-risk oncogenes (HPV-HR) and others as low risk. Among HPV-HR, genotypes 16 and 18, responsible for about 70% of cervical cancer cases, are the preferred targets for HPV vaccines [2]. These prophylactic vaccines initially targeted genotypes 16 and 18 (bivalent vaccine), and 6, 11, 16 and 18 (tetravalent). Genotypes 6 and 11, low oncogenic risk, are responsible for more than 90% of condylomata also called anogenital warts. HPV-HR, other than 16 and 18, is responsible for 30% of cervical cancers. In recent years, a nonavalent vaccine, incorporating some of these high-risk genotypes, has emerged in the market targeting genotypes 6, 11, 16, 18, 31, 33, 45, 52, 58. Three vaccines are available on the market. At a time when our resource-limited countries are initiating HPV vaccination policies, it is important to know the epidemiology of circulating genotypes in our populations for a better analysis of the expected results. This study aimed to determine the prevalence of HPV-HR genotypes in a population of sexually active women in Bobo-Dioulasso, Burkina Faso.

2. Methodology

2.1. Study Population

The study was conducted from September to June 2017 in the Department of Obstetrics and Gynecology and Reproductive Medicine at Bobo-Dioulasso Teaching Hospital in Burkina Faso and enrolled 234 women. Non-pregnant women and girls who presented themselves in a gynecological consultation, freely consenting after information about the interest of the study, were included. Women and girls who are virgins or who have had a hysterectomy have not been included.

2.2. Study Procedures

Each woman benefited from an endocervical swab. The sample thus collected was introduced into a transport medium and stored at −20°C pending the extraction of the DNA. Then a visual inspection of the cervix after application of acetic acid (IVA) and lugol (IVL) was performed. The observed results were transcribed on the data collection sheet. Follow-up and/or care/treatment was offered to women based on IVA/IVL results according to the national protocol.

Extraction of viral DNA from HPV was done using the “DNA-Sorb-A” kit
from SACACE biotechnologies®. Real-time PCR amplification of DNA extracted from endocervical samples was performed to search for human papillomaviruses. This PCR was done using the “HPV Genotypes 14 Real-TM Quant” V67-100 FRT kit (SACACE biotechnologies®, Italy) which makes it possible to detect 14 high-risk human papillomavirus genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and following the protocol provided by the manufacturer.

### 2.3. Statistical Analyses

The data was processed and analyzed using SPSS software version 17.0 and Epi Info 6 software. Chi-square or Fisher tests were used to compare proportions and averages. All the statistical tests of our analysis were considered significant for a threshold of $p < 0.05$.

### 3. Results

#### 3.1. Sociodemographic Characteristics

Sociodemographic characteristics are shown in Table 1. The mean age of women in our study was $30.7 \pm 7.3$ years with a median of 30 years; and 57.7% of women were in the 20 to 30 age group. These were married women in 84.5% of the cases and 43.5% of the women had a socio-professional activity. In 61% of cases, women were educated. Women with less than secondary education level accounted for 39.9% of educated women.

#### 3.2. Prevalence of HPV-HR Infection

Women who were positive for at least one HPV-HR genotype were 48 out of 234, a prevalence of 20.6%.

The kit used made it possible to characterize 12 genotypes of HPV-HR. These were HPV 18, 31, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.

By accumulating HPV-HR genotypes, given that some women were infected with more than one genotype, the total number of genotypes found was 64. Table 2 shows the distribution of women by HPV-HR genotypes isolated.

In the 48 HPV-HR positive women, the number of genotypes per woman ranged from 1 to 5. The number of multiple infections was 11 (22.92%).

The frequencies of the genotypes found are reported in Figure 1.

The most common genotypes were HPV 52 with 11 cases (17.2%) and 66 with 10 cases (15.6%). HPV 18 was found in 4 cases (6.3%) and HPV 16 was never found.

#### 3.3. Prevalence of VIA/VILI Abnormalities

VIA/VILI was abnormal in 16 women (7.0%). The results of HPV-HR carriage are reported in Table 3.

Of these 16 women with VIA/VILI abnormalities, 10 had at least one HPV-HR genotype and none of these had HPV 16 or 18.
Table 1. Sociodemographic characteristics of women (n = 234).

| Characteristics                  | Proportion |
|----------------------------------|------------|
| **Age (years)**                  |            |
| Mean (DS)                        | 30.7 (7.3) |
| ≤ 19, n (%)                      | 5 (2.1)    |
| 20 - 25, n (%)                   | 65 (27.8)  |
| 26 - 30, n (%)                   | 70 (29.9)  |
| 31 - 35, n (%)                   | 39 (16.7)  |
| 36 - 40, n (%)                   | 35 (15.0)  |
| 41 - 45, n (%)                   | 11 (4.7)   |
| 46 - 50, n (%)                   | 8 (3.4)    |
| ≥ 51, n (%)                      | 1 (0.4)    |
| **Marital status, n (%)**        |            |
| Married                          | 198 (84.5) |
| Single                           | 33 (14.0)  |
| Widowed                          | 3 (1.5)    |
| **Education level, n (%)**       |            |
| Illiterate                       | 91 (39.0)  |
| Primary                          | 57 (24.0)  |
| Secondary                        | 75 (32.0)  |
| University                       | 11 (5.0)   |
| **Age at first intercourse (years)** |        |
| Mean (DS)                        | 18.2 (1.8) |
| <19, n (%)                       | 147 (62.8) |
| 19 - 30, n (%)                   | 86 (36.8)  |
| >30, n (%)                       | 1 (0.4)    |
| **Condom use by the partner, n (%)** |        |
| Never                            | 177 (76.0) |
| Sometimes                        | 26 (11.0)  |
| Rarely                           | 19 (8.0)   |
| Every time                       | 12 (5.0)   |

3.4. HPV-HR Infection Carriage by Age and Genotype

The distribution of HPV-HR infection by age and genotype is shown in Table 4.

The number of infected women up to age 30 was 34 out of 140 (24.3%), and 14 out of 94 after 30 years (14.9%) (p = 0.8).

The number of women with multiple genotype infections was 11, a prevalence of 4.7% of the study population, and a proportion of 22.9% of infected women. The prevalence of multiple infections was 7.9% for women less than or equal to
Table 2. Distribution of women by isolated HPV-HR genotypes.

| Genotypes HPV-HR | Number of women | Percentage |
|------------------|-----------------|------------|
| 18               | 2               | 4.17       |
| 31               | 3               | 6.25       |
| 39               | 3               | 6.25       |
| 45               | 2               | 4.17       |
| 51               | 3               | 6.25       |
| **52**           | **7**           | **14.58**  |
| 56               | 2               | 4.17       |
| 58               | 2               | 4.17       |
| 59               | 2               | 4.17       |
| **66**           | **8**           | **16.67**  |
| 68               | 3               | 6.25       |
| 35 + **52**      | 2               | 4.17       |
| 39 + 68          | 2               | 4.17       |
| 68 + 51          | 1               | 2.08       |
| 56 + **66**      | 1               | 2.08       |
| 18 + 59          | 1               | 2.08       |
| 35 + **66**      | 1               | 2.08       |
| 68 + 51 + **52** | 1               | 2.08       |
| 18 + 39 + **52** | 1               | 2.08       |
| 31 + 35 + 51 + 56 + 58 | 1       | 2.08       |
| **Total**        | **48**          | **100.0**  |

Figure 1. Frequency of isolated genotypes in infected women (n = 64).

30 years of age and 2.1% for women over 30 years of age (p = 0.128). No multiple infections were found after 40 years.
Table 3. HPV-HR carriage according to VIA/VILI results.

| HPV-HR carriage | VIA/VILI | Total | p  |
|-----------------|---------|-------|----|
|                 | Positive| Negative|    |
| Positif         | 10      | 38    | 48 |
| Negatif         | 6       | 180   | 186| 0.8 |
| Total           | 16      | 218   | 234|

Table 4. Distribution of HPV-HR by age and genotypes.

| Age groups | Types of infections | HPV-HR Carriage Genotypes (number of women) | Total women | Genotypes |
|------------|---------------------|-------------------------------------------|-------------|-----------|
| ≤19 years  | Isolated            | 52 (1)                                    | 1           | 1         |
|            | Multiples           | 51 + 52 + 68 (1)                          | 1           | 3         |
| 20 - 25 years | Isolated         | 31 (1); 51 (1); 52 (3); 66 (6); 68 (1); 39 (2); | 14          | 14        |
|            | Multiples           | 18 + 59 (1); 35 + 52 (2); 35 + 66 (1); 39 + 68 (2) | 6           | 12        |
| 26 - 30 year | Isolated          | 18 (1); 31 (1); 52 (1); 58 (2); 59 (1); 66 (2); 68 (2) | 10          | 10        |
|            | Multiples           | 31 + 35 + 51 + 56 + 58 (1); 56 + 66 (1) | 2           | 7         |
| 31 - 35 years | Isolated           | 45 (1); 51 (1); 52 (1); 56 (1); 59 (1) | 5           | 5         |
| 36 - 40 years | Isolated           | 18 (1); 39 (1); 51 (1); 52 (1) | 4           | 4         |
|            | Multiples           | 18 + 39 + 52 (1); 51 + 68 (1) | 2           | 5         |
| 41 - 45 years | Isolated          | 31 (1); 45 (1) | 2           | 2         |
| 46 - 50 years | Isolated           | 56 (1) | 1           | 1         |
| Total       |                     | 48    | 64          |

3.5. HPV-HR Carriage According to Sexual and Behavioral Characteristics

The data are shown in Table 5. The frequency of HPV-HR distribution was so high than women had a weekly high frequency of sexual intercourse (p = 0.000).

4. Discussion

The results of this work cannot be generalized at the national level, let alone subregional, given the size of the sample. However, they constitute a link that can be integrated into other results for more comprehensive information on the different genotypes of HPV-HR circulating in Burkina Faso.

In this work we have described the epidemiology of high-risk human papilloma virus infection at a time when Burkina Faso is preparing to start a vaccination program against this virus. The prevalence of HPV-HR infection was 20.6% in our study. Previous studies in Burkina have reported generally higher rates...
In our study, the prevalence of HPV-HR infection was significantly higher among young women. Several authors have reported that this prevalence is inversely proportional to the age of the patients [14] [15] [16].

The prevalence of isolated genotypes varies widely across studies and regions. In the work of Monsenego in the USA, Hibbits in the UK, Pamato in Italy and Mollers in Netherlands HPV 16 is the genotype most frequently found [17] [18] [19] [20]. It is the same for Dols in South Africa [21]. The genotypes most fre-

---

**Table 5. HPV-HR carriage according to sexual and behavioral characteristics.**

| Characteristics                  | HPV-HR       | Total | p   |
|----------------------------------|--------------|-------|-----|
|                                  | Positive     | Negative |     |
| Marital status                   |              |        |     |
| Married                          | 38           | 160    | 198 |
| Single                           | 10           | 23     | 33  |
| Widowed                          | 0            | 3      | 3   |
| Total                            | 48           | 186    | 234 |

| Age at first intercourse         |              |        |     |
| <19 years                        | 29           | 118    | 147 |
| 19 à 30 years                    | 19           | 67     | 86  |
| >30 years                        | 0            | 1      | 1   |
| Total                            | 48           | 186    | 234 |

| Weekly frequency of sexual intercourse |              |        |     |
| 1 to 2                             | 43           | 153    | 196 |
| More than 2                        | 5            | 33     | 38  |
| Total                              | 48           | 186    | 234 |

| Condom use during sex             |              |        |     |
| Never                             | 39           | 138    | 177 |
| Sometimes                         | 2            | 24     | 26  |
| Rarely                            | 4            | 15     | 19  |
| Every time                        | 3            | 9      | 12  |
| Total                             | 48           | 186    | 234 |

| History of genital infections     |              |        |     |
| Yes                               | 20           | 71     | 91  |
| No                                | 28           | 115    | 143 |
| Total                             | 48           | 186    | 234 |
quenty found in our study were HPV 52 and 66 (17.2% and 15.6%) and HPV 16 was not found. The first two genotypes reported in other studies conducted in Burkina Faso are in order of frequency HPV 52, 35, 39, 33, 56, 18, 16 and 66 [3] [4] [5] [6] [7] [22] [23]. Six of these HPV-HR are not covered by the available vaccines in Burkina Faso. In the sub-Saharan subregion, the first two most frequently reported genotypes are 16, 52, 35, 18, 33, 39, 42, 50, 58 and 59 [3] [5] [6] [21] [24] [25].

Overall prevalence of infection as well as multiple infections (2 - 5 genotypes) were higher among young women. The same observation is reported in the literature [4] [5] [18] [26] [27]. All these studies agree that the infection is more important in younger women who have more intense sexual activity, and decreases with age due to the clearance of the virus and the acquisition of some immunity.

Cervical abnormalities detected with IVA/IVL showed no significant association with HPV-HR carriage (p = 0.8560).

Some studied risk factors, such as age at first sexual intercourse, use of condom, marital status, level of education, or previous history of genital infection, were not significantly related to the carriage of HPV-HR. However, we found a statistically significant association between the frequency of sexual intercourse and HPV carriage (p = 0.0000). Indeed, 73.4% of women with HPV had more than two sexual intercourses a week. Figueroa et al also found a highly significant association between high prevalence of HPV and frequent sexual activity [28].

5. Conclusion

Our results highlight a predominance of HPV-HR genotypes not covered by commercially available vaccines. Genotypes mapping at the national level, even sub-regional, seems necessary for us to understand our viral ecology. This would, as a first step, better guide the choice of vaccines to use for our populations; and in the next steps, serve as a basis for the development of multivalent vaccines better adapted to circulating viruses in our resource-limited countries. In the immediate future, the nonavalent vaccine, which has a better coverage of the predominant genotypes, is to be promoted.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1] De Sanjose, S., Quint, W.V.G., Alemany, L., Geraets, D.T., Jo Klaustermeier, J.E., Lloveras, B., Tous, S., Felix, A., Bravo, L.E., Shin, H.-R., Vallejos, C.S., Alonso de Ruiz, P.P., Lima, M.A., Guimera, N., Clavero, O., Alejo, M., Lombart-Bosch, P.A., Cheng-Yang, C. and Bosch, F.X. (2010) Retrospective International Survey and HPV Time Trends Study Group. Lancet Oncology, 11, 1048-1056.
[2] World Health Organization (WHO). Human Papillomavirus (HPV). https://www.who.int/immunization/diseases/hpv/en/

[3] Traoré, I.M.A., Zohoncon, T.M., Dembélé, A., Djigma, F.W., Obiri-Yeboah, D., Traoré, G., Bambara, M., Ouédraogo, C., Traore, Y. and Simporé, J. (2016) Molecular Characterization of High-Risk Human Papillomavirus in Women in Bobo-Dioulasso, Burkina Faso. BioMed Research International, 2016, Article ID: 7092583. https://doi.org/10.1155/2016/7092583

[4] Ouédraogo, R.A., Zohoncon, T.M., Guigma, S.P., Traoré, I.M.A., Ouattara, A.K., Ouédraogo, M., Djigma, F.W., Obiri-Yeboah, D., Ouédraogo, C. and Simporé, S. (2018) Oncogenic Human Papillomavirus Infection and Genotypes Characterization among Sexually Active Women in Tenkodogo at Burkina Faso, West Africa. Papillomavirus Research, 6, 22-26. https://doi.org/10.1016/j.pvr.2018.09.001

[5] Ouédraogo, C.M.R., Rahimya, R.M.L., Zohoncon, T.M., Djigma, F.W., Yonli, A.T., Ouermi, D., Sannid, A., Lankoandé, J. and Simporé, J. (2015) Épidémiologie et caractérisation des génotypes à haut risque de Papillomavirus humain dans une population d’adolescentes sexuellement actives à Ouagadougou. Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 44, 715-722. https://doi.org/10.1016/j.jgyn.2014.12.021

[6] Didelot-Rousseau, M.-N., Nagot, N., Costes-Martineau, V., Vallès, X., Ouédraogo, A., Konaté, I., et al. (2006) Human Papillomavirus Genotype Distribution and Cervical Squamous Intraepithelial Lesions among High-Risk Women with and without HIV-1 Infection in Burkina Faso. British Journal of Cancer, 95, 355-362. https://doi.org/10.1038/sj.bjc.6603252

[7] Ouédraogo, C.M.R., Djigma, F.W., Bisseye, C., Sagna, T., Zéba, M., Ouermi, D., et al. (2011) Épidémiologie et caractérisation des génotypes de papillomavirus humain dans une population de femmes à Ouagadougou. Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 40, 633-638. https://doi.org/10.1016/j.jgyn.2011.05.012

[8] Chaturvedi, A.K., Katki, H., Hildesheim, A., Rodriguez, A., Quint, W., Schiffman, M., et al. (2011) Human Papillomavirus Infection with Multiple Types: Pattern of Coinfection and Risk of Cervical Cancer. The Journal of Infectious Diseases, 203, 910-920. https://doi.org/10.1093/infdis/iqj139

[9] Howell-Jones, R., De Silva, N., Akpan, M., Oakeshott, P., Carder, C., Coupland, L., et al. (2012) Prevalence of Human Papillomavirus (HPV) Infections in Sexually Active Adolescents and Young Women in England, Prior to Widespread HPV Immunization. Vaccine, 30, 3867-3875. https://doi.org/10.1016/j.vaccine.2012.04.006

[10] Confortini, M., Carozzi, F., Zappa, M., Ventura, L., Iossa, A., Cariaggi, P., et al. (2010) Human Papillomavirus Infection and Risk Factors in a Cohort of Tuscan Women Aged 18-24: Results at Recruitment. BMC Infectious Diseases, 10, 157. https://doi.org/10.1186/1471-2334-10-157

[11] Ngabo, F., Franceschi, S., Baussano, I., Umulisa, M.C., Snijders, P.J.F., Uytterlinde, A.M., Lazzarato, F., Tenet, V., Gatera, M., Binagwaho, A. and Clifford, G.M. (2016) Human Papillomavirus Infection in Rwanda at the Moment of Implementation of a National HPV Vaccination Programme. BMC Infectious Diseases, 16, 225. https://doi.org/10.1186/s12879-016-1539-6

[12] Muñoz, N., Bosch, F.X., De Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K., et al. (2003) Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. The New England Journal of Medicine, 348, 518-527.
[13] Organisation mondiale de la santé (OMS) (2007) La lutte contre le cancer du col de l’utérus: Guide des pratiques essentielles. OMS, Genève.

[14] Bardin, A., Vaccarella, S., Clifford, G.M., Lissowska, J., Rekosz, M., Bobkiewicz, P., et al. (2008) Human Papilloma Virus Infection in Women with and without Cervical Cancer in Warsaw, Poland. *European Journal of Cancer, 44*, 557-564. [https://doi.org/10.1016/j.ejca.2007.12.001](https://doi.org/10.1016/j.ejca.2007.12.001)

[15] Kjaer, S.K., Breugelman, G., Munk, C., Junge, J., Watson, M. and Iftner, T. (2008) Population-Based Prevalence, Type- and Age Specific Distribution of HPV in Women before Introduction of an HPV-Vaccination Program in Denmark. *International Journal of Cancer, 123*, 1864-1870. [https://doi.org/10.1002/ijc.23712](https://doi.org/10.1002/ijc.23712)

[16] Gavillon, N., Vervaet, H., Deriaux, E., Terrosi, P., Graesslin, O. and Quereux, C. (2010) How Did I Contract Human Papillomavirus (HPV). *Gynécologie Obstétrique & Fertilité, 38*, 199-204. [https://doi.org/10.1016/j.gyobfe.2010.01.003](https://doi.org/10.1016/j.gyobfe.2010.01.003)

[17] Monsonego, J., Cox, J.T., Behrens, C., Sandri, M., Franco, E.L., Yap, P.S. and Huh, W. (2015) Prevalence of High-Risk Human Papillomavirus Genotypes and Associated Risk of Cervical Precancerous Lesions in a Large U.S. Screening Population: Data from the Athena Trial. *Gynecologic Oncology, 137*, 47-54. [https://doi.org/10.1016/j.ygyno.2015.01.551](https://doi.org/10.1016/j.ygyno.2015.01.551)

[18] Hibbitts, S., Rieck, G.C., Hart, K., Powell, N.G., Beukenholdt, R., Dallimore, N., McRea, J., Hauke, A., Tristram, A. and Fiander, A.N. (2006) Human Papillomavirus Infection: An Anonymous Prevalence Study in South Wales, UK. *British Journal of Cancer, 95*, 226-232. [https://doi.org/10.1038/sj.bjc.6603245](https://doi.org/10.1038/sj.bjc.6603245)

[19] Panatto, D., Amicizia, D., Tanzi, E., Bianchi, S., Frati, E.R., Zotti, C.M., Lai, P.L., Bechini, A., Rossi, S. and Gasparini, R. (2013) Prevalence of Human Papillomavirus in Young Italian Women with Normal Cytology: How Should We Adapt the National Vaccination Policy? *BMC Infectious Diseases, 13*, 575. [https://doi.org/10.1186/1471-2334-13-575](https://doi.org/10.1186/1471-2334-13-575)

[20] Mollers, M., Boot Hein, J., Vriend Henrike, J., King Audrey, J., van den Broek Ingrid, V.F., van Bergen Jan, E.A., Brink Antoinette, A.T., Wolfs Petra, F.G., Hoebe Christian, J.P., Meijer Chris, J.L., van der Sande Marianne, A.B. and de Melker Hester, E. (2013) Prevalence, Incidence and Persistence of Genital HPV Infections in a Large Cohort of Sexually Active Young Women in the Netherlands. *Vaccine, 31*, 394-401. [https://doi.org/10.1016/j.vaccine.2012.10.087](https://doi.org/10.1016/j.vaccine.2012.10.087)

[21] Dols, J.A., Reid, G., Brown, J.M., Tempelman, H., Bontekoe, T.R., Quint, W.G. and Boon, M.E. (2012) HPV Type Distribution and Cervical Cytology among HIV-Positive Tanzanian and South African Women. *ISRN Obstetrics and Gynecology, 2012*, Article ID: 514146. [https://doi.org/10.5402/2012/514146](https://doi.org/10.5402/2012/514146)

[22] Zohoncon, T.M., Bisseye, C., Djigma, F.W., Yonli, A.T., Compaoe, T.R., Sagna, T., Ouermi, D., Ouédraogo, C.M.R., Pietra, V., Nikiéma, J.-B., Akpona, S.A. and Simpore, J. (2013) Prevalence of HPV High-Risk Genotypes in Three Cohorts of Women in Ouagadougou (Burkina Faso). *Mediterranean Journal of Hematology and Infectious Diseases, 5*, e2013059. [https://doi.org/10.4084/mjhid.2013.059](https://doi.org/10.4084/mjhid.2013.059)

[23] Ouédraogo, C., Zohoncon, T.M., Traoré, E.M.A., Ouattara, S., Bado, P., Ouedraogo, C.T., Djigma, F.W., Ouermi, D., Obiri-Yeboah, D., Lompo, O., Akpona, S.A. and Simpore, J. (2016) Distribution of High-Risk Human Papillomavirus Genotypes in Precancerous Cervical Lesions in Ouagadougou, Burkina Faso. *Open Journal of Obstetrics and Gynecology, 6*, 196-204. [https://doi.org/10.4236/ojog.2016.64025](https://doi.org/10.4236/ojog.2016.64025)

[24] Thomas, J.O., Herrero, R., Omigbodun, A.A., Ojemakinde, K., Ajayi, I.O., Fawole,
A., Oladepto, O., Smith, J.S., Arslan, A., Munoz, N., Snijders, P.J.F., Meijer, C.J.L.M. and Franceschi, S. (2004) Prevalence of Papillomavirus Infection in Women in Ibadan, Nigeria: A Population-Based Study. *British Journal of Cancer*, **90**, 638-645.

[25] Baay, M.F.D., Kjetland, E.F., Ndlovu, P.D., Deschoolmeester, V., Mduluza, T., Gomo, E., Friis, H., Midzi, N., Gwanzura, L., Mason, P.R., Vermorken, J.B. and Gundersen, S.G. (2004) Human Papillomavirus in a Rural Community in Zimbabwe: The Impact of HIV Co-Infection on HPV Genotype Distribution. *Journal of Medical Virology*, **73**, 481-485. https://doi.org/10.1002/jmv.20115

[26] Rousseau, M.C., Abrahamowicz, M., Villa, L.L., Costa, M.C., Rohan, T.E. and Franco, E.L. (2003) Predictors of Cervical Coinfection with Multiple Human Papillomavirus Types. *Cancer Epidemiology, Biomarkers & Prevention*, **12**, 1029-1037.

[27] Wall, S.R., Scherf, C.F., Morison, L., Hart, K.W., West, B., Ekpo, G., Fiander, A.N., Man, S., Gelder, C.M., Walraven, G. and Borysiewicz, L.K. (2005) Cervical Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Rural Gambia, West Africa: Viral Sequence Analysis and Epidemiology. *British Journal of Cancer*, **93**, 1068-1076. https://doi.org/10.1038/sj.bjc.6602736

[28] Figueroa, J.P., Ward, E., Luthi, T.E., Vermud, S.H., Brathwaite, A.R. and Burk, R.D. (1995) Prevalence of Human Papillomavirus among STD Clinic Attenders in Jamaica: Association of Younger Age and Increased Sexual Activity. *Sexually Transmitted Diseases*, **22**, 114-118. https://doi.org/10.1097/00007435-199503000-00007